Ticlopidine compliance enhancement: A community pharmacy based study

Journal of Pharmacoepidemiology

Volumn 8, Issue 1, 2000, Pages 51-66

  Fincham, Jack E ^a   Wallace, Ivory A ^b  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Compliance; Pharmacist; Stroke; Ticlopidine

Indexed keywords

CLOPIDOGREL; DIPYRIDAMOLE; TICLOPIDINE;

ARTICLE; CAREGIVER; CHRONIC DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; PATIENT COMPLIANCE; PHARMACIST; PHARMACY; PRESCRIPTION; STROKE;

EID: 0033992042     PISSN: 08966966     EISSN: None     Source Type: Journal    
DOI: 10.1300/J055v08n01_04     Document Type: Article

References (19)

1. 1997 Heart and Stroke Statistical Update, American Heart Association. Dallas, TX: American Heart Association, 1997
2. Longstreth WT, Nelson LM, Kepsell TD et al. Cigarette smoking, alcohol use, and subarachnoid hemorrhage. Stroke 1992; 23: 1242-1249.
3. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. British Medical Journal 1994; 308: 81-106.
4. Helgason CM, Bolin KM, Hoff JA et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25(12): 2331-2336.
5. Savi P, Heilmann E, Nurden P et al. Clopidogrel: an antithrombotic drug acting on the ADP-dependent activation pathway of human platelets. Clin Appl Thrombosis Hemostatis 1996, 2: 35-42.
6. Schafer AI. Antiplatelet therapy. Am J Med 1996; 101: 199-209.
7. Gent M, Blakely JA, Easton JD et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Design, organization, and baseline results. Stroke 1988; 19: 1203-1210.
8. Haas WK, Easton D, Adams HP et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. New England Journal of Medicine 1989; 321: 501-507.
9. Raps EC, Galetta SL. Stroke prevention therapies and management of patient subgroups. Neurology 1995; 45(2 Suppl 1): S19-S24.
10. Murray JC, Kelly MA, Gorelick PB. Ticlopidine: a new antiplatelet agent for the secondary prevention of stroke. Neuropharmacology 1994; 17(1): 23-31.
11. Saltiel E, Ward A. Ticlopidine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in platelet dependent disease states. Drugs 1987; 34: 222-262.
12. Weinberg PD, Rozenberg BDK, Yarnold RR et al. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med 1998; 128(7): 541-544.
13. Bronstein KS, Chadwick LR. Ticlopidine hydrochloride: its current use in cerebrovascular disease. Rehabilitative Nursing 1994; 19(1); 17-20.
14. Evans RL, Hendrick RD, Haselkorn JK et al. The family's role in stroke rehabilitation. A review of the literature. Am J Phys Med Rehabil 1992; 73(3): 135-139.
15. Evans RL, Griffith J, Haselkorn JK et al. Poststroke family function: an evaluation of the family's role in rehabilitation. Rehabilitative Nursing 1992; 17(3): 127-131.
16. Komiya T, Kudo M, Urabe T. Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease. Assessment by platelet aggregation testing. Stroke 1994; 25(12): 2337-2342.
17. Pullar T, Birtwell AJ, Wiles PG et al. Use of a pharmacological indicator to compare compliance with tablets prescribed to be taken once, twice or three times daily. Clinical Pharmacological and Therapeutics 1988; 44(5): 540-545.
18. Gregoire JP, Guilbert R, Archambault A et al. Measurement of noncompliance to antihypertensive medication using pill counts and pharmacy records. Journal of Social and Administrative Pharmacy 1997; 14(4): 198-207.
19. Schueler K. Cost-effectiveness issues in hypertension control. Can J Public Health 1994; 85: Suppl 2: S54-56.